Q-omics provides the consensus-scored ALDH7A1P2 profile across patient tissues and cancer cell-line models. ALDH7A1P2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ALDH7A1P2 is differentially expressed in 2, with the highest sampling consensus in ESCA. Additionally, ALDH7A1P2 RNA expression shows 11,537 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, ESCA, and GBM as cancer lineages where ALDH7A1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALDH7A1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALDH7A1P2 survival associations across molecular data types. ALDH7A1P2 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALDH7A1P2 RNA expression–survival associations across cancer types. High ALDH7A1P2 expression shows unfavorable associations in MESO, KIRC, THCA, CESC and HNSC, but favorable associations in ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .019). Together, the overview and detailed table identify MESO as the clearest survival context for ALDH7A1P2 RNA expression.
This table summarizes ALDH7A1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for ALDH7A1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALDH7A1P2 shows lower tumor expression in ESCA and LUSC. The ESCA box plot shows higher ALDH7A1P2 RNA expression in normal versus tumor tissue (log2 FC = −0.105, t-test p = .002).
This table shows molecular features associated with ALDH7A1P2 in patient tissues and cancer cell lines. In patient samples, ALDH7A1P2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
